Gilles Salles

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France
    Clin Lymphoma Myeloma 8:356-8. 2008
  2. ncbi Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon, Lyon, France
    Leuk Lymphoma 51:399-405. 2010
  3. ncbi Current and future management of follicular lymphoma
    Gilles Salles
    Hospices Civils de Lyon, Universite Lyon 1, Pierre Benite, France
    Int J Hematol 96:544-51. 2012
  4. ncbi Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Gilles Salles
    Hospices Civils de Lyon, Hematologie, Universite de Lyon, Unité Mixte de Recherche UMR 5239, Centre National de la Recherche Scientifique CNRS, Pierre Benite, France
    Blood 119:5126-32. 2012
  5. ncbi Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
    Gilles Salles
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 112:4824-31. 2008
  6. ncbi [Chronic lymphoproliferative disorders]
    Gilles Salles
    Service d hématologie Centre hospitalier Lyon Sud, 69495 Pierre Benite
    Rev Prat 52:966-71. 2002
  7. ncbi Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
    Gilles Salles
    Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France
    Blood 117:7070-8. 2011
  8. ncbi Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
    Gilles Salles
    Hospices Civils de Lyon, Universite Claude Bernard, UMR CNRS5239, Pierre Benite, France
    Lancet 377:42-51. 2011
  9. ncbi Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index
    Ewa Lech-Maranda
    Equipe Pathologie des Cellules Lymphoïdes, UMR CNRS 5239, Universite Claude Bernard, Lyon, France
    Arch Immunol Ther Exp (Warsz) 58:131-41. 2010
  10. ncbi CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases
    Lucile Baseggio
    Laboratoire d Hématologie Cellulaire Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon
    Haematologica 95:604-12. 2010

Detail Information

Publications79

  1. ncbi Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France
    Clin Lymphoma Myeloma 8:356-8. 2008
    ..Herein, we briefly review the spectrum of immunodeficiency-associated lymphoproliferative disorders (LPDs), discuss the immune deficit induced by rituximab, and speculate on its possible association with EBV reactivation in this patient...
  2. ncbi Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon, Lyon, France
    Leuk Lymphoma 51:399-405. 2010
    ..Relapse occurring after rituximab-containing therapy appears to be more aggressive than that occurring after chemotherapy alone. The outcome of retreatment, in terms of progression-free survival, is similar to that of primary treatment...
  3. ncbi Current and future management of follicular lymphoma
    Gilles Salles
    Hospices Civils de Lyon, Universite Lyon 1, Pierre Benite, France
    Int J Hematol 96:544-51. 2012
    ..Since most patients will likely survive for many years, the quality and duration of response as well as the short- and long-term side effects of the treatments should be carefully weighted during this prolonged therapeutic management...
  4. ncbi Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Gilles Salles
    Hospices Civils de Lyon, Hematologie, Universite de Lyon, Unité Mixte de Recherche UMR 5239, Centre National de la Recherche Scientifique CNRS, Pierre Benite, France
    Blood 119:5126-32. 2012
    ..Data from this study suggest that GA101 was well tolerated and demonstrated encouraging activity in patients with previously treated NHL up to doses of 2000 mg. This trial is registered at www.clinicaltrials.gov as NCT00517530...
  5. ncbi Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
    Gilles Salles
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 112:4824-31. 2008
    ..This study's clinical trial was registered at the National Institutes of Health website as no. NCT00136552...
  6. ncbi [Chronic lymphoproliferative disorders]
    Gilles Salles
    Service d hématologie Centre hospitalier Lyon Sud, 69495 Pierre Benite
    Rev Prat 52:966-71. 2002
    ..A better definition of these entities should allow to clarify therapeutic recommendations before more efficient treatments become available...
  7. ncbi Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
    Gilles Salles
    Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France
    Blood 117:7070-8. 2011
    ..These data demonstrate that the IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy...
  8. ncbi Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
    Gilles Salles
    Hospices Civils de Lyon, Universite Claude Bernard, UMR CNRS5239, Pierre Benite, France
    Lancet 377:42-51. 2011
    ..We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen...
  9. ncbi Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index
    Ewa Lech-Maranda
    Equipe Pathologie des Cellules Lymphoïdes, UMR CNRS 5239, Universite Claude Bernard, Lyon, France
    Arch Immunol Ther Exp (Warsz) 58:131-41. 2010
    ..This model may help to identify patients in a given IPI risk group for whom more accurate and risk-adapted treatment could be advised...
  10. ncbi CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases
    Lucile Baseggio
    Laboratoire d Hématologie Cellulaire Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon
    Haematologica 95:604-12. 2010
    ....
  11. ncbi Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis
    Herve Ghesquieres
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d Hematologie, France
    J Clin Oncol 24:5234-41. 2006
    ..The characteristics and prognosis of these particular DLBCL are not well known...
  12. ncbi In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia
    Lucile Baseggio
    Service d Hematologie Biologique, UMR5239 Pathologies des cellules lymphoïdes, Universite Claude Bernard, Lyon, France
    Br J Haematol 158:489-98. 2012
    ..Moreover, most of these CLLs harboured a low mutation load of BCL6 gene and unmutated FAS (CD95) loci, which points to a post-germinal-centre cellular origin...
  13. ncbi Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud
    Bernard Lemieux
    Hematology Department, Hospices Civils de Lyon, , Pierre-Benite, France
    Hematol J 5:467-71. 2004
    ..3 months, P = 0.09). The second treatment was well tolerated. Thus, a second treatment with rituximab should be considered, alone or in combination with chemotherapy, for patients who progress after a first response to rituximab...
  14. ncbi CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma
    Lucile Baseggio
    Laboratoire d Hématologie cellulaire, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Mod Pathol 24:993-1003. 2011
    ..Consequently, if ICOS constitutes an additional feature for the diagnosis of angioimmunoblastic T-cell lymphoma, it appears less sensitive than CD10 expression for the detection of circulating neoplastic T cells...
  15. ncbi Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases
    Alexandra Traverse-Glehen
    Hospices Civils de Lyon, Service d Anatomie Pathologique, Centre Hospitalier Lyon Sud, Universite Lyon 1, Pierre Benite, France UMR CNRS 5239 Equipe Pathologie des Cellules Lymphoides, Pierre Benite, France
    Histopathology 62:876-93. 2013
    ..To describe 76 cases of splenic marginal zone lymphoma (SMZL), including correlations with clinical and other characteristics...
  16. ncbi Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
    Francoise Berger
    Pathology Service, Centre Hospitalier Lyon Sud, Equipe d Accueil 3737, Pathologie des Cellules Lymphoides, Universite Claude Bernard, Lyon, France
    Clin Lymphoma 5:220-4. 2005
    ..Molecular IgVH gene analysis has confirmed this heterogeneity, particularly within SMZL, with mutated and unmutated cases. Further studies are needed to clarify the pathogenesis of these MZLs and their relationship with LPL...
  17. ncbi Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
    Herve Ghesquieres
    Centre Leon Berard, Lyon, France
    Blood 120:2650-7. 2012
    ..The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582...
  18. ncbi Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma
    Sophie Gazzo
    Service d Hematologie Biologique, Centre Hospitalier Lyon Sud Hospices Civils de Lyon et Université Claude Bernard Lyon I, EA 3737, 69495 Pierre Benite, Cedex 69495, France
    Cancer Genet Cytogenet 175:159-65. 2007
    ..This also confirms the localization in the vicinity of band 7q32 of putative candidate gene(s) involved in the pathogenic development of the disease...
  19. ncbi Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
    Alexandra Traverse-Glehen
    Service d Anatomie Pathologique Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
    Blood 111:2253-60. 2008
    ..These results, as well as the clinical evolution, show that those lymphoma cases represent a homogeneous group distinct from SMZL and reminiscent of hairy cell leukemia variant, perhaps corresponding to a separate lymphoma entity...
  20. ncbi Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells
    Amel Chebel
    Universite Lyon 1, CNRS UMR 5239, Ecole Normale Supérieure ENS, Universite Claude Bernard, Hospices Civils de Lyon, Faculté Lyon Sud, Oullins 69921
    J Biol Chem 284:35725-34. 2009
    ..Thus, we show for the first time the direct involvement of NFAT1 in the transcriptional regulation of hTERT...
  21. ncbi Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    Equipe d Accueil Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, Lyon, France
    Arch Immunol Ther Exp (Warsz) 61:165-74. 2013
    ..VEGF may be a useful marker for selecting the patients for whom new treatment approaches, especially those based on VEGF inhibitors, could be recommended...
  22. ncbi Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients
    Florence Lachenal
    Hospices Civils de Lyon, Department of Internal Medicine, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Medicine (Baltimore) 86:282-92. 2007
    ..The current study underlines the diversity of presenting manifestations of angioimmunoblastic T-cell lymphoma...
  23. ncbi Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity
    Alexandra Traverse-Glehen
    Service d Anatomie Pathologique, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, France
    Discov Med 13:253-65. 2012
    ..This review will report literature data and discuss the differential diagnosis, particularly with HCL-V...
  24. ncbi Predictors of prescription errors involving anticancer chemotherapy agents
    Florence Ranchon
    Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department Université Lyon 1, Ecole Doctorale Interdisciplinaire Sciences Santé, Lyon, France
    Eur J Cancer 48:1192-9. 2012
    ..The majority of medication errors that harm patients relate to the prescribing process. Our study aimed to identify the predictors of prescription errors involving anticancer chemotherapy agents...
  25. ncbi Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL
    Emmanuel Bachy
    Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Pierre Bénite 69495, France
    Best Pract Res Clin Haematol 24:257-70. 2011
    ..This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment...
  26. ncbi Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    , , Lyon, France
    Eur Cytokine Netw 17:60-6. 2006
    ..The plasma concentration of IL-10 may be a useful marker for evaluation of disease activity...
  27. ncbi Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France
    Pascal Seve
    Department of Internal Medicine, Lyon Civil Hospices, Lyon, France
    Eur J Gastroenterol Hepatol 16:1361-5. 2004
    ..We sought to determine whether such an association could be found in patients treated in the Rhone-Alpes region in south-east France. Our main interest was to identify histological subtypes preferentially linked to HCV...
  28. ncbi Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
    Catherine Thieblemont
    Service d Hematologie Clinique, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Cancer 104:1434-41. 2005
    ..The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high-dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL)...
  29. ncbi Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma
    Adrien Chauchet
    Department of Hematology, Centre Hospitalier Universitaire Lyon Sud, Pierre Benite, France
    J Hematol Oncol 5:27. 2012
    ..Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors...
  30. ncbi Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation
    Adeline Augereau
    Epigenetic and Telomeric Regulations, Lyon Sud Medicine Faculty, Lyon 1 University, Centre National de la Recherche Scientifique CNRS Unité Mixte de Recherche UMR 5239, Pierre Benite, France
    Blood 118:1316-22. 2011
    ..0464) and TINF2 (coding for TIN2; P = .0177). We propose that telomeric deprotection in the early step of CLL is not merely the consequence of telomere shortening but also of shelterin alteration...
  31. ncbi Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
    Bertrand Coiffier
    Hematology, Hospices Civils de Lyon, Lyon, France
    Lancet Oncol 12:773-84. 2011
    ..We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting...
  32. ncbi Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL)
    Catherine Thieblemont
    Hematology Departement, Hospices Civils de Lyon, Claude Bernard University, 69495 Pierre Benite, France
    Leuk Lymphoma 45:711-4. 2004
    ..In conclusion, maintenance alemtuzumab therapy seems to increase the time to progression and the survival, without adding hematological toxicities and infectious complications. More patients are needed to confirm this observation...
  33. ncbi Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants
    Judith Trotman
    Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney, Sydney, Australia
    J Clin Oncol 29:3194-200. 2011
    ..We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study...
  34. ncbi Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma
    Alexandra Traverse-Glehen
    Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France
    Oncology (Williston Park) 26:92-9, 103-4. 2012
    ....
  35. ncbi Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma
    Sophie Gazzo
    , Centre Hospitalier Lyon Sud, , Lyon, France
    Haematologica 88:31-8. 2003
    ....
  36. ncbi Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001
    Catherine Thieblemont
    Hematology Department, Hospices Civils de Lyon Claude Bernard University 69495 Pierre Benite, France
    Leuk Lymphoma 44:257-62. 2003
    ..Considering the natural bias of a retrospective analysis, surgery or chemotherapy was associated with a similar outcome in patients with MALT lymphoma after antibiotics failure...
  37. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    ..We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma...
  38. ncbi High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia
    Sandrine Hayette
    Service d Hematologie Biologique, Centre Hospitalier Lyon Sud, Pierre Benite France, Hospices Civils de Lyon, Lyon, France
    PLoS ONE 7:e51527. 2012
    ..Its quantification should be implemented to the genetic profile used to stratify patients for therapeutical strategies and should be useful to identify patients who may benefit from therapy based on demethylating agents...
  39. ncbi Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis
    Catherine Thieblemont
    Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Blood 103:2727-37. 2004
    ..This study demonstrates that SLL, splenic MZL, and MCL possess specific transcriptional profiles that may be relevant to the pathogenesis and the diagnosis of these histologic subtypes...
  40. ncbi Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia
    Delphine Poncet
    Laboratoire de Biologie Moleculaire et de Cellule, Centre National de la Recherche Scientifique UMR5239, IFR128, Faculté de médecine Lyon Sud, Universite Lyon 1, Lyon, France
    Blood 111:2388-91. 2008
    ..001). This differential expression pattern suggests that both telomerase down-regulation and changes in telomeric proteins composition are involved in the pathogenesis of B-CLL...
  41. ncbi S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53
    Wei Wen Chien
    Universite Claude Bernard Lyon 1, CNRS UMR 5239, ENS HCL, Faculte de Medecine, Pierre Benite, France
    Cell Cycle 9:3286-96. 2010
    ....
  42. ncbi [Prognostic factors in lymphomas]
    Emmanuel Bachy
    Hospices Civils de Lyon, Universite Claude Bernard, Service d hématologie Centre hospitalier Lyon Sud, 69496 Pierre Bénite Cedex
    Rev Prat 60:65-8. 2010
    ..Numerous biomarkers obtained on fresh or frozen tissue using molecular techniques are currently described and may help to optimize the clinical care of lymphoma patients tomorrow...
  43. ncbi Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation
    Tagrid Kaddar
    LBMC, CNRS UMR5239, IFR128, Faculté de médecine Lyon Sud, Universite Lyon 1, Pierre Benite, France
    Biol Cell 101:511-24. 2009
    ..These data prompted us to search for and validate novel targets of miR-16...
  44. ncbi Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
    Florence Ranchon
    Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite Université Lyon 1, EMR UCBL HCL 3738, Lyon, France
    BMC Cancer 11:478. 2011
    ..This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and costs...
  45. ncbi Maintenance therapy in follicular lymphoma
    Anne Sophie Michallet
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, Lyon, France
    Curr Opin Oncol 23:449-54. 2011
    ..This article reviews the potential benefit of maintenance therapy for patients with follicular lymphoma...
  46. ncbi Prognostic systems for lymphomas
    Anna Johnston
    Service d Hematologie, Hospices Civils de Lyon, 69495 Pierre Benite, Lyon, France
    Hematol Oncol Clin North Am 22:839-61, viii. 2008
    ..The current challenge, translating these molecular findings into clinical practice, requires the validation of those biomarkers in large cohorts of patients...
  47. ncbi Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors
    Cecilia Frecha
    INSERM U758, Human Virology Department, Universite de Lyon, Ecole Normale Superieure de Lyon, Lyon, France
    Blood 114:3173-80. 2009
    ..These new LVs will facilitate antibody production and the study of gene functions in these healthy and cancer immune cells...
  48. ncbi Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    Equipe d Accueil 3737 Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, Lyon, France
    Blood 103:3529-34. 2004
    ..76, P =.00035) and OS (RR =.78, P =.0015). These results indicate that IL-10 production contributes to the clinical course of DLBCL and that this phenomenon involves a substantial genetic component...
  49. ncbi The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate
    Nicolas Rachinel
    Faculté de Médecine Lyon Sud Charles Mérieux, 165, Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    Curr Hematol Malig Rep 4:196-201. 2009
    ..Blocking the cross-talk between the tumor microenvironment and lymphoma cells may thus represent a promising new strategy for treating B-cell malignancies...
  50. ncbi Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies
    Fadela Bouafia
    , Centre Hospitalier Lyon Sud, Chemin du Grand Revoyet, , France
    Bull Cancer 91:E229-40. 2004
    ..We conclude that there are characteristic alterations in serum LDH profiles in patients with haematopoietic malignancies and that some of these may be more interesting in terms of prognostic value than total serum LDH...
  51. ncbi Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection
    Alexandra Traverse-Glehen
    , , France
    Haematologica 90:470-8. 2005
    ..Moreover, a biased usage of certain sequences suggests that tumor cells in SMZL may be subjected to antigen selection...
  52. ncbi Cytogenetic and molecular analysis of 12 cases of primary cutaneous marginal zone lymphomas
    Arnaud de la Fouchardiere
    , Centre Hospitalier Lyon Sud, , France
    Am J Dermatopathol 28:287-92. 2006
    ..These data also underline that fluorescence in situ analysis on routine skin punch biopsies represents a reliable tool for the detection of chromosomal changes, but requires consistent dermal infiltration...
  53. ncbi Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte
    Emmanuel Bachy
    Service d Hematologie, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    J Clin Oncol 28:822-9. 2010
    ..Therefore, response-adapted therapy aiming to achieve a CR should be considered as first-line treatment...
  54. ncbi Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma
    Delphine Rolland
    Universite Joseph Fourier, INSERM U836 Equipe 7, Grenoble, France
    Cancer Chemother Pharmacol 61:855-63. 2008
    ..The cytotoxic activity of the farnesyltranseferase inhibitor R115777 was evaluated in cell lines representative of mantle cell lymphoma (MCL)...
  55. ncbi T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Pierre Raynaud
    Department of Hematology and Pathology, INSERM 475 and CHU 34295 Montpellier, France
    Hum Pathol 39:194-200. 2008
    ....
  56. ncbi Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Blood 108:2540-4. 2006
    ..After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients...
  57. ncbi Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study
    Jean Henri Bourhis
    Division of Hematology, Department of Medicine, Institut Gustave Roussy, 94800 Villejuif, France
    Haematologica 92:1083-90. 2007
    ....
  58. ncbi Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients
    Catherine Thieblemont
    Hematology Department, Centre Hospitalier Lyon Sud, , France
    Clin Lymphoma 3:41-7. 2002
    ..We conclude that splenectomy is an efficient treatment for splenic MZL, but that it may be delayed until the occurrence of symptoms or cytopenia...
  59. ncbi The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
    Kerry J Savage
    Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:3871-9. 2003
    ..In almost all cases, c-REL was localized to the nucleus, consistent with activation of the NF-kappa B pathway. These studies identify a molecular link between MLBCL and cHL and a shared survival pathway...
  60. ncbi The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas
    Eva M Murga Penas
    University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Haematologica 92:405-9. 2007
    ..FISH revealed the involvement of the immunoglobulin locus in the t(11;14;18). Rapid amplification of cDNA ends (RACE)-PCR to detect the involved partner gene on 6q showed exclusively wild-type API2 and MALT1 sequences...
  61. ncbi Splenic marginal-zone lymphoma: a distinct clinical and pathological entity
    Catherine Thieblemont
    Haematology Department, Centre Hospitalier Lyon Sud, Pierre, , France
    Lancet Oncol 4:95-103. 2003
    ..Splenectomy is considered the first-line treatment of choice for splenic MZL; it results in only partial remission, but responses are generally sufficient for correcting cytopenia, improving quality of life, and increasing survival...
  62. ncbi Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma
    Bertrand Coiffier
    Blood 104:1584-5; author reply 1585-6. 2004
  63. ncbi [News in therapeutic management of chronic lymphoid leukemia]
    Anne Sophie Michallet
    Hopital Edouard Herriot, Place d Arsonval, 69437 Lyon Cedex 03
    Bull Cancer 92:249-56. 2005
    ..In parallel, age, co morbidities and the notion of the risk-adapted strategy have also an important impact adding...
  64. ncbi Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
    Stefano Monti
    The Broad Institute, Cambridge, MA, USA
    Blood 105:1851-61. 2005
    ..These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets...
  65. ncbi Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
    Sylvain Choquet
    Hematology Unit, CHU La Pitié Salpêtrière Hospital, 47 bd de l Hopital, 75651 Paris Cedex 14, France
    Blood 107:3053-7. 2006
    ..We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments...
  66. ncbi Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial
    Christophe Ferme
    Groupe d Etudes des Lymphomes de l Adulte, Hopital Saint Louis, Paris, France
    J Clin Oncol 20:467-75. 2002
    ....
  67. ncbi Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
    Christophe Ferme
    Department of Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France
    N Engl J Med 357:1916-27. 2007
    ..Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure...
  68. ncbi [Pathological and clinical correlations in primary cutaneous B-cell lymphomas: a series of 44 cases]
    Arnaud de la Fouchardiere
    Service d Anatomie Pathologique, Hopital Croix Rousse, Lyon
    Ann Pathol 25:8-17. 2005
    ..histological and clinical relationship study of 44 cases of primary cutaneous B cell lymphoma, classified according to WHO classification...
  69. ncbi High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial
    Danielle Canioni
    Department of Pathology, Assistance Publique Hopitaux de Paris, Hopital Necker Enfants Malades, Universite Paris Descartes, 149 rue de Sevres, 75015, Paris, France
    J Clin Oncol 26:440-6. 2008
    ..We tried to establish whether intratumoral macrophage count (MC) definitely is able to predict the outcome of FL patients in the rituximab era...
  70. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
    ..This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas...
  71. ncbi Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma
    Jacek Nowak
    Institute of Haematology and Blood Transfusion, Warsaw, Poland
    Genes Chromosomes Cancer 46:500-7. 2007
    ..We conclude that 8.1 AH is an important contributor to NHL outcome. In contrast to A*01-B*08-TNF(-308A, the remaining alleles (Cw*07, DRB1*03, LTA+252G) associated with the 8.1 AH seem to be its passive components...
  72. ncbi Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium
    Daphne de Jong
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 25:805-12. 2007
    ....
  73. ncbi Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome
    Przemyslaw Juszczynski
    Department of Hematology and Department of Clinical Immunology, Medical University of Lodz, Poland
    Blood 100:3037-40. 2002
    ..63; P <.0001, RR = 1.51) and null HLA DRB1*02 alleles (P =.015, RR = 1.18; P <.0001, RR = 1.25) as independent factors for FFP and OS. These results indicate the existence of at least 2 inherited factors involved in NHL outcome...
  74. ncbi The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell
    Lucile Baseggio
    Haematologica 91:1717-9. 2006
    ..Interestingly, with the use of an appropriate antibody association, this feature is easily and rapidly observed on flow cytometry graphics...
  75. ncbi Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte
    René Olivier Casasnovas
    Service d Hematologie Clinique, Hopital Le Bocage, Centre Hospitalier Universitaire Dijon, Dijon, France
    J Clin Oncol 25:1732-40. 2007
    ..Usual prognosis scoring systems are actually unable to identify this small subset of patients with good confidence, pointing out the need for additional prognostic biomarkers...
  76. ncbi [The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas]
    Przemysław Juszczyński
    Oddział Chorób Rozrostowych, Regionalny Ośrodek Onkologiczny, Wojewódzki Szpital Specjalistyczny im M Kopernika w Lodzi
    Przegl Lek 62:1417-21. 2005
    ..009 and p = 0.017, respectively). These data indicate that innate immunity as reflected by the genetic propensity of the host to regulate TNF expression influences clinical course and outcome of NHL...
  77. ncbi Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas
    Sidonie Niclot
    , , , , , Paris, France
    Blood 108:278-85. 2006
    ....
  78. ncbi Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma
    Sophie Gazzo
    Haematologica 90:1708-9. 2005
    ..These data underline that FISH analysis must be be systematically performed in cases with an aberrant presentation to prevent a misdiagnosis...
  79. ncbi Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sézary syndrome
    Evelyne Callet-Bauchu
    Haematologica 92:1277-8. 2007
    ..2) translocation. Molecular analyses identified a new transcript, an e8a4 BCR-ABL fusion mRNA which could be responsible for the disease transformation...